Themes / Group
Inactive · established relationshipLatest completed snapshot · Aug 21 · 16:11 ET

MARKET-DISCOVERED GROUP

Biopharmaceuticals and Care

THE TRADER READRecurring relationship, inactive in the latest snapshot

6 of 12 measured SPY-adjusted paths align to the downside across 7.8 effective names. Common-bar coverage spans 12 of 15 cohort members. Capital-flow agreement is 41%, so the basket is not yet clean. No verified headline preceded the measured move.

Price breadth13 up · 2 down-0.2% median path versus SPY
Capital-flow alignment41%Price breadth is not yet confirmed by flow
Activity nowCalmActivity score 32/100 · lift 0.8×
Evidence depth5 episodes27 observed active sessions
EVIDENCE CLOCK

What happened, in timestamp order

4 timed events · 10:10–15:55 ET
TIMING READNo verified timestamped headline was found within 24 hours of the first measured price move in the available common-bar window. The move currently reads as market-led or unexplained.
  1. 5-minute inferenceMRK registered the first material downside path

    -0.46% session path at the threshold · MRK

  2. 5-minute inferenceACAD registered a material upside path

    +0.66% session path at the threshold · ACAD

  3. 5-minute inferenceEXEL registered a material upside path

    +0.87% session path at the threshold · EXEL

  4. 5-minute inferenceBMY registered a material upside path

    +0.40% session path at the threshold · BMY

2 earlier filing context receipts

TUE, AUG 4AMGN filing documented shared operating contextdemand / volume affecting revenue · date precision only

WED, AUG 5BMRN filing documented shared operating contextdemand / volume affecting revenue · date precision only

Headline times and retained activity confirmations are point-in-time evidence. Price order is inferred from aligned 5-minute bars. Filing evidence has date precision only and is context, not an intraday catalyst claim.
THEME CONSTRUCTION

Broad move or one-stock disguise?

SPY-adjusted 5m paths

Observed movement is broad across 7.8 effective names. BMRN represents 18.4% of absolute path energy; 6 of 12 members align with the down relative path.

ConstructionBroad18.4% from the largest path
Effective names7.8 / 1212 of 15 cohort members had common bars
Direction breadth6/12 aligneddownside relative path · 4 counter-moving
Largest moverBMRN 18.4%35.6% from the top two paths
BMRN18.4%Aligned contributor · path -1.28% · basket -0.11pp
MRK17.2%Aligned contributor · path -1.19% · basket -0.10pp
ACAD13.6%Counter-move · path +0.94% · basket +0.08pp
NBIX11.9%Aligned contributor · path -0.82% · basket -0.07pp
REGN11.9%Aligned contributor · path -0.82% · basket -0.07pp
GILD9.8%Aligned contributor · path -0.68% · basket -0.06pp
INCY7.1%Aligned contributor · path -0.49% · basket -0.04pp
GSK4.1%Counter-move · path +0.28% · basket +0.02pp
AMGN3.4%Counter-move · path +0.23% · basket +0.02pp
HALO1.6%Counter-move · path +0.11% · basket +0.01pp
EXEL0.9%Flat / inactive path · path +0.07% · basket +0.01pp
BMY0.1%Flat / inactive path · path +0.01% · basket +0.00pp
Top six names by movement share are shown. Movement share measures absolute 5-minute path energy; signed basket contribution is equal-weight. Neither is a portfolio weight or causal attribution.

01 · WHAT IS HAPPENING

The move, the flow and who is driving it

Price breadth, unusual activity and signed capital flow are separate observations
HOW THE PRICE MOVE SPREAD

Observed session sequence

5-minute bars · inferred
  1. MRK moved lower firstFirst member to clear the material path threshold · path -0.46%
  2. ACAD registered a material higher path0m after the first price move · path +0.66%
  3. EXEL registered a material higher path0m after the first price move · path +0.87%
  4. BMY registered a material higher path0m after the first price move · path +0.40%
  5. NBIX registered a material lower path60m after the first price move · path -0.40%
  6. BMRN registered a material lower path95m after the first price move · path -0.74%

Sequence inferred from aligned 5-minute price paths; it is not a causal ordering.

RELATIVE CO-MOVEMENT

How the members are behaving together

SPY-adjusted
Aug 21 · 10:10 ET13:25 ETAug 21 · 15:55 ET
Group median -0.24%Strongest relative path ACADWeakest relative path BMRN

Observed member paths adjusted against SPY. The dashed marker shows when the median move first cleared a material threshold; shading marks the latest 20% of the observed window.

02 · WHY IT MATTERS

Why now and where the move could travel

Context and lead/lag links are evidence, not proof of causation or a forecast
WHY NOW

Verified recent context

0 items

No verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.

WHY THIS GROUP EXISTS

Shared filing context

13/15 members covered

Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across ACAD, BMRN, BMY, EXEL, GILD, HALO, INCY, MRK, NBIX, REGN, RPRX, VRTX.

demand / volume affecting revenue

“As a result of the cyberattack, its orders and sales for certain products were negatively affected.”

AMGN 10-Q · 2026-08-05
demand / volume

“For example, we lost potential VOXZOGO revenues in the past due to strong demand outpacing our projections and supply constraints.”

BMRN 10-Q · 2025-10-28
product pipeline / R&D affecting expense

“38 Operating expenses Operating expenses were as follows (dollar amounts in millions): Three months ended March 31, 2026 2025 Change Operating expenses: Cost of sales $ 2,744 $ 2,968 (8) % % of product sales 33.4 % 37.7 % % of total revenues 31.8 % 36.4 % Research and development $ 1,719 $ 1,486 16 % % of product sales 20.9 % 18.9 % % of total revenues 19.9 % 18.2 % Selling, general and administrative $ 1,602 $ 1,687 (5) % % of product sales 19.5 % 21.4 % % of total revenues 18.6 % 20.7 % Other $ (113) $ 830 * Total operating expenses $ 5,952 $ 6,971 (15) % * Change in excess of 100% Cost of sales Cost of sales decreased to 31.8% of total revenues for the three months ended March 31, 2026, due to lower amortization expense from acquisition-related assets, partially offset by higher profit share and royalty expense and changes in our sales mix.”

AMGN 10-Q · 2026-05-01
CONFIRMATION NETWORK

Outsiders and cross-asset links

0 outsiders confirming

No qualified cross-asset lead/lag link is available for this group.

Filing-linked outsiders test whether the move is spreading beyond the established cohort.

ABBVNot confirming

MRK · text peer

BCRXNot confirming

REGN · text peer

ZLABNot confirming

MRK · text peer

TEVANot confirming

VRTX · text peer

03 · WHO IS IN IT

Member participation

Unusual activity and daily price direction are shown separately
AMGNVRTXBMYGSKGILDREGNMRKBMRNINCYRPRXEXELTAKACADNBIXHALO

8/15 active13 rising · 2 falling

MemberUnusual activityToday's moveRead now
AMGNAmgen Inc.
Most unusual · 100/100
+1.3%
Counter-move / dispersionActive in 37% of observed group sessions
VRTXVertex Pharmaceuticals Incorporated
Elevated · 74/100
+1.5%
Flow confirmerActive in 14.8% of observed group sessions
BMYBristol-Myers Squibb Company
Elevated · 74/100
+2.3%
Active; unclassifiedActive in 22.2% of observed group sessions
GSKGSK plc
Elevated · 73/100
+0.9%
Counter-move / dispersionActive in 18.5% of observed group sessions
GILDGilead Sciences, Inc.
Elevated · 54/100
+1.8%
Aligned price + flowActive in 14.8% of observed group sessions
REGNRegeneron Pharmaceuticals, Inc.
Elevated · 51/100
+0.8%
Aligned price + flowActive in 25.9% of observed group sessions
MRKMerck & Company, Inc.
Elevated · 47/100
+2.3%
Aligned price + flowActive in 29.6% of observed group sessions
BMRNBioMarin Pharmaceutical Inc.
Elevated · 43/100
-1.5%
Aligned path contributorActive in 22.2% of observed group sessions
INCYIncyte Corporation
Quiet · 35/100
+0.5%
Watch / laggardActive in 11.1% of observed group sessions
RPRXRoyalty Pharma plc
Quiet · 31/100
+1.2%
Watch / laggardActive in 18.5% of observed group sessions
EXELExelixis, Inc.
Quiet · 28/100
+0.8%
Watch / laggardActive in 14.8% of observed group sessions
TAKTakeda Pharmaceutical Company Limited
Quiet · 28/100
+0.2%
Watch / laggardActive in 33.3% of observed group sessions
ACADACADIA Pharmaceuticals Inc.
Quiet · 25/100
+1.6%
Watch / laggardActive in 3.7% of observed group sessions
NBIXNeurocrine Biosciences, Inc.
Quiet · 22/100
-0.3%
Watch / laggardActive in 14.8% of observed group sessions
HALOHalozyme Therapeutics, Inc.
Quiet · 21/100
+1.9%
Watch / laggardActive in 7.4% of observed group sessions
View exact member values
TICKERCompanyRole nowTodayObserved historyTrader interpretation
AMGNAmgen Inc.Most unusual+1.3%37% of 27 sessionsMost unusual activity in this snapshot; performance direction may differ.
VRTXVertex Pharmaceuticals IncorporatedParticipating+1.5%14.8% of 27 sessionsPrice participation with accumulating signed flow.
BMYBristol-Myers Squibb CompanyParticipating+2.3%22.2% of 27 sessionsPrice participation is not yet confirmed by per-name flow.
GSKGSK plcParticipating+0.9%18.5% of 27 sessionsPrice participation is not yet confirmed by per-name flow.
GILDGilead Sciences, Inc.Participating+1.8%14.8% of 27 sessionsPrice participation with accumulating signed flow.
REGNRegeneron Pharmaceuticals, Inc.Participating+0.8%25.9% of 27 sessionsPrice participation with accumulating signed flow.
MRKMerck & Company, Inc.Participating+2.3%29.6% of 27 sessionsPrice participation with accumulating signed flow.
BMRNBioMarin Pharmaceutical Inc.Participating-1.5%22.2% of 27 sessionsPrice participation is not yet confirmed by per-name flow.
INCYIncyte CorporationQuiet / lagging+0.5%11.1% of 27 sessionsNot participating yet; a breadth test or a genuine divergence.
RPRXRoyalty Pharma plcQuiet / lagging+1.2%18.5% of 27 sessionsNot participating yet; a breadth test or a genuine divergence.
EXELExelixis, Inc.Quiet / lagging+0.8%14.8% of 27 sessionsNot participating yet; a breadth test or a genuine divergence.
TAKTakeda Pharmaceutical Company LimitedQuiet / lagging+0.2%33.3% of 27 sessionsNot participating yet; a breadth test or a genuine divergence.
ACADACADIA Pharmaceuticals Inc.Quiet / lagging+1.6%3.7% of 27 sessionsNot participating yet; a breadth test or a genuine divergence.
NBIXNeurocrine Biosciences, Inc.Quiet / lagging-0.3%14.8% of 27 sessionsNot participating yet; a breadth test or a genuine divergence.
HALOHalozyme Therapeutics, Inc.Quiet / lagging+1.9%7.4% of 27 sessionsNot participating yet; a breadth test or a genuine divergence.

04 · HAS THIS HAPPENED BEFORE

Identity history versus measured outcomes

Structural recurrence is not the same as a validated trading outcome
POINT-IN-TIME LIVE OUTCOMES

Observed follow-through

5/5 events completed
30 minutes+0.40%67% continuation · n=3Median MFE +0.66% · MAE -0.48%
60 minutes+0.22%67% continuation · n=3Median MFE +0.66% · MAE -0.48%
Session close+0.57%100% continuation · n=1Median MFE +0.61% · MAE -0.81%
Next-session close-0.15%33% continuation · n=3Median MFE +0.66% · MAE -0.48%
Only point-in-time live watcher observations and conservative same-day EOD observations are included. Later backfills and replay runs are excluded.
moderate structural support

5 completed episodes across 27 active sessions provide moderate historical support. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.

Structural support37 daysHow often the cohort identity was observed
Completed episodes5Separate periods of broad group activity
Active sessions27Completed session observations, not trades
2026-07-28 → 2026-08-1914 active sessionsNo name was active through every recorded session
2026-07-21 → 2026-07-233 active sessionsNo name was active through every recorded session
2026-07-15 → 2026-07-162 active sessions25% composition consistency through the episode
2026-07-07 → 2026-07-104 active sessionsNo name was active through every recorded session
2026-06-29 → 2026-07-024 active sessions8.3% composition consistency through the episode
MEMBER CONSISTENCY IN OBSERVED ACTIVE SESSIONS
AMGN37% · 4 episodes
TAK33.3% · 3 episodes
MRK29.6% · 2 episodes
REGN25.9% · 2 episodes
BMRN22.2% · 2 episodes
BMY22.2% · 3 episodes
GSK18.5% · 2 episodes
RPRX18.5% · 2 episodes
EXEL14.8% · 4 episodes
GILD14.8% · 1 episode
NBIX14.8% · 2 episodes
VRTX14.8% · 3 episodes
INCY11.1% · 2 episodes
HALO7.4% · 1 episode
ACAD3.7% · 1 episode